Login / Signup

Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept.

Hanna HongChase J WehrleMingyi ZhangSami FaresHenry StitzelDavid GaribBassam EstfanSuneel KamathSmitha KrishnamurthiWen Wee MaTeodora KuzmanovicElizabeth AzzatoEmrullah YilmazJamak Modaresi EsfehMaureen Whitsett LingannaMazhar KhalilAlejandro PitaAndrea SchlegelJaekeun KimR Matthew WalshCharles MillerKoji HashimotoDavid Choon Hyuck KwonFederico Aucejo
Published in: Cancers (2024)
Patients with ctDNA positivity experienced recurrence at a higher rate than the ctDNA- patients, indicating the potential role of ctDNA in predicting recurrence after curative-intent transplant. Based on sequential testing, LT has the potential to clear ctDNA, demonstrating the capability of LT in the treatment of systemic disease. Transplant providers should be aware of the potential of donor-derived cell-free DNA and improved approaches are necessary to address such concerns.
Keyphrases
  • circulating tumor
  • cell free
  • circulating tumor cells
  • liver metastases
  • end stage renal disease
  • prognostic factors
  • ejection fraction
  • newly diagnosed
  • human health
  • peritoneal dialysis